Kidswell Bio Corporation (4584.T)
JPY 145.0
(5.84%)
JPY 145.0
(5.84%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 5.08 Billion JPY | 30.57% |
| 2022 | 3.89 Billion JPY | 12.23% |
| 2021 | 3.47 Billion JPY | -11.78% |
| 2020 | 3.93 Billion JPY | 9.52% |
| 2019 | 3.59 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 4.6 Billion JPY | -9.36% |
| 2023 Q1 | 3.04 Billion JPY | -21.83% |
| 2023 Q4 | 5.08 Billion JPY | -2.17% |
| 2023 Q3 | 5.19 Billion JPY | 62.77% |
| 2023 Q2 | 3.19 Billion JPY | 4.91% |
| 2023 FY | 5.08 Billion JPY | 30.57% |
| 2022 Q2 | 4.25 Billion JPY | 0.0% |
| 2022 FY | 3.89 Billion JPY | 12.23% |
| 2022 Q4 | 3.89 Billion JPY | -6.68% |
| 2022 Q3 | 4.17 Billion JPY | -2.03% |
| 2021 FY | 3.47 Billion JPY | -11.78% |
| 2020 FY | 3.93 Billion JPY | 9.52% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | 22.821% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -319.799% |
| GNI Group Ltd. | 62.39 Billion JPY | 91.849% |
| Linical Co., Ltd. | 18.53 Billion JPY | 72.57% |
| Trans Genic Inc. | 9.81 Billion JPY | 48.165% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | 9.737% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 26.786% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | 12.564% |
| AnGes, Inc. | 28.89 Billion JPY | 82.398% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -486.383% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 96.765% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -214.198% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | -0.281% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | -16.912% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -109.036% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -114.275% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 26.618% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -190.362% |
| PeptiDream Inc. | 67.12 Billion JPY | 92.424% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -149.219% |
| Ribomic Inc. | 3.54 Billion JPY | -43.366% |
| SanBio Company Limited | 5.04 Billion JPY | -0.758% |
| Healios K.K. | 15.15 Billion JPY | 66.443% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -313.373% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | -68.619% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -244.981% |
| StemRIM | 9.08 Billion JPY | 43.992% |
| CellSource Co., Ltd. | 6.87 Billion JPY | 26.079% |
| FunPep Company Limited | 2.49 Billion JPY | -104.146% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | -94.205% |
| Stella Pharma Corporation | 3.82 Billion JPY | -33.108% |
| TMS Co., Ltd. | 3.55 Billion JPY | -43.063% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | 11.999% |
| Cuorips Inc. | 6.18 Billion JPY | 17.773% |
| K Pharma,Inc. | 3.31 Billion JPY | -53.461% |
| Takara Bio Inc. | 123.2 Billion JPY | 95.872% |
| ReproCELL Incorporated | 9.05 Billion JPY | 43.822% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | -87.291% |
| StemCell Institute Inc. | 6.54 Billion JPY | 22.276% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 27.233% |
| CellSeed Inc. | 2.46 Billion JPY | -106.246% |